XML 40 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Janssen Collaboration Agreement (Details) - USD ($)
3 Months Ended 9 Months Ended
Jul. 13, 2017
Dec. 31, 2017
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Jun. 30, 2017
Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
License and collaboration revenue - related party     $ 8,781,000 $ 0 $ 8,781,000 $ 0    
Deferred revenue - related party     41,739,000   41,739,000     $ 0
Receivable from collaboration partner - related party     520,000   520,000     0
Change in Contract with Customer, Asset and Liability [Abstract]                
Contract with Customer, Asset, Net     520,000   520,000   $ 0 0
Contract with Customer, Asset, Period Increase     520,000   520,000      
Contract with Customer, Liability     41,739,000   41,739,000   $ 0 $ 0
Contract with Customer, Liability, Period Increase     50,000,000   50,132,000      
Contract with Customer, Liability, Revenue Recognized     (8,261,000)   (8,393,000)      
Janssen Biotech, Inc. [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
License and collaboration revenue - related party     $ 400,000   $ 400,000      
Collaborative Arrangement, Product [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Collaborative arrangement, percentage of development costs incurred     20.00%   20.00%      
Collaborative Arrangement, Product [Member] | Janssen Biotech, Inc. [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Nonrefundable upfront payment $ 50,000,000              
Collaborative arrangement, percentage of development costs incurred     80.00%   80.00%      
License and collaboration revenue - related party     $ 8,800,000   $ 8,800,000      
Revenue recognition, amount     8,400,000   8,400,000      
Deferred revenue - related party     100,000   100,000      
Change in Contract with Customer, Asset and Liability [Abstract]                
Contract with Customer, Asset, Net     54,200,000   54,200,000      
Contract with Customer, Liability, Revenue Recognized         8,400,000      
Collaborative Arrangement, Product [Member] | Janssen Biotech, Inc. [Member] | Scenario, Forecast [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Contingent consideration receivable   $ 25,000,000            
Collaboration agreement, detail capital required for commercial launch, percent (up to)   30.00%            
First Opt-in [Member] | Collaborative Arrangement, Product [Member] | Janssen Biotech, Inc. [Member] | Scenario, Forecast [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Forfeiture of remaining rights and payment of cost, penalty percentage   50.00%            
Future opt-in payment eligible to receive under collaboration arrangement   $ 125,000,000            
Second Opt-in [Member] | Collaborative Arrangement, Product [Member] | Janssen Biotech, Inc. [Member] | Scenario, Forecast [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Future opt-in payment eligible to receive under collaboration arrangement   200,000,000            
Aggregate milestone payment   590,000,000            
Deferred Revenue [Member] | Collaborative Arrangement, Product [Member] | Janssen Biotech, Inc. [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Deferred revenue - related party     $ 41,700,000   $ 41,700,000      
Cost-Sharing Payments [Member] | Collaborative Arrangement, Product [Member] | Janssen Biotech, Inc. [Member] | Scenario, Forecast [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Contingent consideration receivable   $ 4,200,000